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INTRODUCTION
Asthma is a chronic inflammatory disorder of the airways char-
acterized by bronchial hyperresponsiveness, reversible airflow 
limitation, and respiratory symptoms. Asthma is a common 
disease worldwide, affecting more than 300 million individuals 
in the developed world.
1 The prevalence of asthma varies wide-
ly among countries, ranging from 2.1% to 4.4% in developing 
countries such as Albania, China, and Indonesia to 29.1% to 
32.2% in Australia, New Zealand, and the United Kingdom.
2 In 
Korea, the prevalence of asthma in elementary school children 
increased remarkably from 5.7% in 1981 to 17.0% in 1995 and 
decreased slightly thereafter (13.0% in 2000 and 10.5% in 2006).
3,4 
In 2001, the prevalence of asthma tended to be less in adults than 
in children (3.6%). However, among the elderly (aged 65 years or 
older), asthma prevalence was high at 12.7%.
5 Additionally, the 
high prevalence of asthma comes at a high cost. According to a 
study that used the Korea National Health Insurance claims da-
tabase, in 2004, the estimated total annual cost of asthma was 
more than $4 billion in Korea [unpublished data]. 
For this reason, many studies have been conducted to deter-
mine more effective treatments for asthma, and major advanc-
es in asthma medications have been achieved. However, signif-
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icant heterogeneity in the efficacy and adverse reactions of 
asthma therapeutics has been observed, and efforts have been 
made to clarify the potential genetic sources of this individual 
variability. The purpose of this review was to present an over-
view of pharmacogenomics for current asthma treatment. 
PHARMACOTHERAPY
The goal of asthma treatment is to achieve and maintain clini-
cal control. Asthma treatment can be divided into four main 
categories: the avoidance of risk factors that cause asthma ex-
acerbations such as allergens, viral infections, pollutants, envi-
ronmental control to reduce allergens, immunotherapy, and 
pharmacotherapy. Pharmacotherapy plays a main role in con-
trolling and preventing asthma. The current treatment guide-
lines recommend a stepwise approach to pharmacologic thera-
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Major classes of medication in asthma management include bronchodilating B2-agonists, anti-inflammatory inhaled corticosteroids, leukotriene 
modifiers and theophyllines. However, all asthmatics do not respond to the same extent to a given medication. Available data suggest that a sub-
stantial range of individual variability, as much as 70%, may be due to genetic characteristics of each patient. Pharmacogenomics offers the poten-
tial to optimize medications for individual asthmatics by using genetic information to improve efficacy or avoid adverse effects. The best-studied 
case of the potential contribution of pharmacogenomics to treatment response in asthma comes from studies on human B2 adrenergic receptors. In 
addition, genetic variation in B2-adrenergic receptor (Arg16Gly) may predict response to anticholinergics for the treatment of asthma. In case of in-
haled corticosteroids, a recent investigation using a traditional SNP-based approach identified a gene for corticotropin releasing hormone receptor 1 
as a potential marker of response. Another major pathway that has been investigated is the pathway underlying response to cysteinyl leukotriene 
receptor antagonist. It is likely that in the near future, pharmacogenomic approaches based on individual genetic information will be introduced into 
an asthma treatment guideline and this guideline will allow us to identify those who have the best chance to respond to a specific medication.
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py based on asthma control (Fig. 1).
1 
Medications to treat asthma can be classified as controllers or 
relievers. Controllers are medications taken daily on a long-term 
basis to keep asthma under clinical control chiefly through their 
anti-inflammatory effects. Controlling medications include in-
haled corticosteroids (ICSs), long-acting B2-agonists (LABAs), 
leukotriene modifiers, methylxanthines and omalizumab. Re-
lievers are medications used on an as-needed basis, which act 
quickly to reverse bronchoconstriction and relieve its symp-
toms. Short-acting B2-agonists (SABAs), systemic glucocorti-
costeroids and short-acting anticholinergics are included as re-
lievers. 
INTERINDIVIDUAL VARIABILITY IN ANTIASTHMATIC 
DRUG RESPONSES 
The achievement of treatment goals is less than optimal in 
many patients. Even in patients with an apparently identical 
clinical phenotype, the response to drug treatment may vary re-
markably. Commonly, some patients respond to a given treat-
ment, while others fail to respond. Variability in the individual 
asthma treatment response may be due to many factors, includ-
ing the severity and type of disease, treatment compliance, con-
current illness, other medications taken (drug-drug interactions), 
environmental exposures, and age. However, up to an estimat-
ed 70% of the variability in therapeutic responses to pharmaco-
therapy might be due to genetic variability. Results of a random-
ized, stratified, double-blind, parallel-group study of 3,421 pa-
tients with uncontrolled asthma showed that even treatment 
that is fully consistent with current guidelines fails to control 
asthma in up to 25% of patients.
6 A study on treatment response 
to glucocorticosteroids, B2 adrenergic agonists and an experi-
mental leukotriene inhibitor found that 60-80% of the variance 
in drug response may be due to individual genetic differences.
7 
This value corresponds to the maximum limit of genetic vari-
ance, and indicates that a clinically relevant part of the re-
sponse to the main classes of asthma drugs may be due to ge-
netic determinants. The genetic variations include a polymor-
phism in a gene or a random DNA position (single nucleotide 
polymorphism, SNP) or variations in a series of associated al-
leles (haplotypes, linkage disequilibrium) and may be related 
to drug metabolism (pharmacokinetics) or to the drug target 
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Asthma education / Environmental control
As needed rapid-
acting B2-agonist As needed rapid-acting B2-agonist
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Level of Control
Controlled
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Treatment Action
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Step up until controlled
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Fig. 1.  Management approach based on control for 5-year-old children, adolescents, and adults.
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(pharmacodynamics). These results also suggest that current 
treatment guidelines for asthma therapy should be reviewed 
considering the latest information about genetic determinants 
of responses to commonly used asthma therapies. 
PHARMACOGENOMICS
Pharmacogenomics is the study of how inheritance influenc-
es a drug response. A greater understanding of the genetic de-
terminants of the drug response may lead to improved patient 
treatment. By predicting patients at risk for severe toxicity, or 
those likely to benefit from a particular treatment based on a 
patient’s genetic profile, pharmacogenomics can realize the ulti-
mate goal of individualized asthma therapy. Furthermore, phar-
macogenomics offers a new tool for discovering new targets for 
drug development. To date, asthma pharmacogenomic investi-
gations have focused on B2-agonists, leukotriene antagonists, 
and glucocorticosteroids. In addition to the pharmacogenomic 
evidence for these three medications, our pharmacogenomic 
data on anticholinergics will be presented.
B2-AGONISTS
B2-Agonists represent the most important bronchodilator 
drugs used for treating acute asthma. Because of the many re-
ports on individual differences in response to B2-agonists and 
tachyphylaxis, investigators have focused on the B2-adrenergic 
receptor (B2AR) gene. Responses to this drug are currently the 
most investigated pharmacogenomic approaches in asthma. 
The B2AR is a G protein-coupled receptor with seven trans-
membrane segments and 413 amino acids. Activation of B2AR 
with B2-agonist binding uncouples stimulatory G proteins, fol-
lowed by activation of adenyl cyclase, which converts ATP to 
cAMP and activates protein kinase A.
8 Increased cAMP levels 
and phosphorylation of proteins by protein kinase A indirectly 
cause relaxation of bronchial smooth muscle and mast cell sta-
bilization. 
B2-Agonist pharmacogenomic studies have focused on the ef-
fect of ADRB2 variants on the response or adverse outcomes of 
B2-agonists. ADRB2, encoding B2AR, contains 2,011 nucleotide 
base pairs on the long arm of chromosome 5 (5q31-32). Among 
10 identified functional SNPs, three coding polymorphisms lo-
cated at positions 16 (rs1042713), 27 (rs1042714) and 164 (rs 
1800888) have been studied. These SNPs result in arginine sub-
stitution for glycine (Arg16→Gly), glutamine substitution for 
glutamic acid (Gln27→Glu) and threonine substitution for iso-
leucine (Thr164→Ile). The Arg16→Gly and Gln27→Glu polymor-
phisms are frequent in Asians, however, Thr164→Ile polymor-
phism is only and rarely observed in European Americans.
9
In vitro response to B2-agonists
In vitro studies using transfected cell lines that express B2AR 
showed that the Gly16 receptor has an enhanced agonist-pro-
moted downregulation relative to Arg16; a greater concentra-
tion of B2-agonist was needed to downregulate the Glu27 re-
ceptor than Gln27 (Fig. 2).
10 
In vivo acute response to B2-agonists
Our clinical study of 195 children showed that the bronchodi-
lating response was significantly higher in subjects homozy-
gous for Arg16 than in those homozygous for Gly16 (62.8% ver-
sus 46.7%, respectively; P=0.04). Moreover, patients with the ho-
mozygous Arg16Gln27 haplotype pairs and those heterozygous 
for Arg16Gln27/Gly16Glu27 showed the highest bronchodilat-
ing responses (62.8% and 61.6%, respectively), and the patients 
with the homozygous Gly16Gln27 haplotype pairs showed the 
lowest response (43.2%).
11 Similarly, results from one study 
showed that albuterol-evoked forced expiratory volume in 1 s 
(FEV1) was higher and the response was more rapid in Arg16 
homozygotes than carriers of the Gly16 variant (18% versus 
4.9%, respectively; P<0.03).
12
Response to chronic dosing with B2-agonists
Israel et al.,
13 performed retrospective genotyping of 190 sub-
jects who had mild asthma and who were randomized to al-
buterol as-needed or two puffs four times daily. The results 
showed that Arg16 homozygous asthmatics on regular albuter-
ol for 16 weeks had reduced morning peak expiratory flow rates 
from baseline (30.5±12.1 L/min) relative to homozygous Arg16 
asthmatics on as-needed albuterol (P=0.012).
 Moreover, ho-
mozygous Gly16 asthmatics were not affected by regular treat-
ment.
 A study of the relationships between B2AR polymor-
phisms and clinical outcomes showed that homozygous Arg16 
asthmatics taking regularly scheduled salbutamol had a higher 
rate of asthma exacerbation than those taking a placebo.
14 
A study by Wechsler et al.,
15 showed that homozygous Arg16 
was possibly associated with a reduced response to LABA as 
well, and this has led to concerns that the use of combined ICS/
Fig. 2.  Long-term agonist-promoted downregulation of the wild-type and mu-
tated B2-adrenergic receptor (modified from Green et al.
10).
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LABA medications would result in poor clinical outcomes in 
patients with polymorphisms of this gene. However, a recent 
study suggested that the Gly16Arg polymorphism does not pre-
dict worse outcomes in moderate-to-severe asthmatic patients 
treated with LABA/ICS.
16 In that study, asthmatic patients were 
treated with ICS/LABA, and the B2AR polymorphism had no 
effect on the asthma exacerbations; therefore, it offers reassur-
ance for the continued use of combined ICS/LABA therapy.
INTERACTION BETWEEN GENETIC VARIATIONS AND 
GLUCOCORTICOIDS
Glucocorticoids are the most potent anti-inflammatory drugs 
used for asthma treatment. Inhaled glucocorticoids are estab-
lished as the first-line treatment in adults and children with per-
sistent asthma. However, clinical studies have shown that about 
5% to 10% of all patients with asthma, and up to 35% of those 
with severe disease, have reduced responses to glucocorticos-
teroid therapy.
17 
Many cases of glucocorticoid resistance may be due to muta-
tions or polymorphisms present in the glucocorticoid receptor 
(GR) gene (NR3C1).
18 Four of these mutations are missense 
mutations (D641V, G679S, V729I, and I747M), which lead to de-
creased affinity for the steroid and an impaired ability to acti-
vate gene transcription. The N363S polymorphism (rs6195) ap-
pears to be associated with an increased sensitivity to glucocor-
ticoids.
Corticotropin releasing hormone receptor 1 (CRHR1) is the 
primary receptor mediating the release of corticotrophin-re-
leasing hormone, which regulates endogenous cortisol levels 
and encoded by CRHR1 gene. Genetic variation in CRHR1 is 
associated with an increased pulmonary function response to 
inhaled corticosteroids in adults and children.
19 Over an 8-week 
period, the mean FEV1 improvement in adults homozygous for 
the minor allele (GAT) was 13.7% versus 5.5% in those homozy-
gous for the wild-type allele. Improvement in those heterozy-
gous for the GAT haplotype was intermediate between the two 
groups, suggesting an additive effect. 
More recently, attention has been focused on the possible im-
plication of chromatin remodeling and glucocorticoid resis-
tance in asthma. Histone acetyl transferase (HAT) regulates gene 
expression through acetylation of core histones, and histone 
deacetylase (HDAC) mediates gene repression. The level of 
HAT activity is elevated in patients with asthma, and HDAC ac-
tivity is reduced in bronchial biopsies, which may contribute to 
local proinflammatory cytokine production.
20 Glucocorticoids 
switch off inflammatory genes in those with asthma by directly 
inhibiting HAT activity and by recruiting HDAC2 to activate nu-
clear factor κB (NF-κB) complexes. Furthermore, dexametha-
sone-induced repression of Th2 cytokines requires the GR to 
transport HDAC1 to GATA3 located on the Th2 gene promoters. 
HDAC6 inactivation leads to hyperacetylation of heat shock 
protein 90 (Hsp90), a GR chaperone protein, and dissociation 
from the GR-hsp90 complex results in a reduction in nuclear 
translocation.
21 HDAC10 is a member of the class II HDACs and 
is found to interact with other HDACs. Known two splice vari-
ants of HDAC10 could affect the function of other HDACs.
22 In 
summary, the anti-inflammatory actions of glucocorticoids re-
quire the presence or activation of distinct HDACs and HDAC 
polymorphisms may be associated with glucocorticoid respon-
siveness.
INTERACTION BETWEEN GENETIC VARIATIONS AND A 
LEUKOTRIENE MODIFIER
Antileukotriene therapies inhibit leukotriene synthesis by in-
hibiting 5-lipoxygenase (5-LO) or by blocking the cysteinyl leu-
kotriene receptor. In a retrospective study assessing the phar-
macogenetic significance 5-LO gene (ALOX5) Sp1/Egr1 poly-
morphism, those possessing only mutant ALOX5 alleles were 
relatively resistant to treatment with the ALOX5 inhibitor ABT-
761. Mean FEV1 improved in wild-type homozygotes (18.8± 
3.6%) and heterozygotes (23.3±6%) compared to homozygote 
mutant individuals (-1.2±2.9%).
23 Similarly, a significantly high-
er FEV1 response to the leukotriene receptor antagonist (LTRA) 
montelukast was observed for the ALOX5 SNP (rs2115819) GG 
homozygotes compared to those with the AA and AG geno-
types (P=0.017).
24 
Studies on the leukotriene C4 synthase gene (LTC4S) poly-
morphism (-444 A>C, rs730012) show an improved response to 
LTRAs in patients carrying the C allele.
24,25 Although some stud-
ies have failed to reproduce these findings,
26-29 perhaps due to 
different populations and different endpoints, this polymor-
phism is a good candidate for pharmacogenomics. 
A pharmacogenetic study of multi-drug related protein 1 
(MRP1), one of the LTC4 transmembrane transporters for the 
extracellular space, showed that the presence of the T allele (in-
tronic SNP, rs119774) significantly improved FEV1 response to 
montelukast in asthmatics.
24 
In a Korean study, the cysteinyl leukotriene receptor 1 gene 
(CYSLTR1) polymorphism, the minor alleles of both the pro-
moter and coding SNPs [-945 C>T (rs321029) and 927 T>C 
(rs320995)] were associated with a requirement for montelu-
kast in 89 aspirin-intolerant asthmatics (P<0.02).
26 In addition, 
a study of thromboxane A2 receptor gene (TBXA2R) polymor-
phism showed that asthmatic children with combinations of 
the TBXA2R+924T>C homozygote (TT) and TBXA2R+795 T>C 
hetero- or homozygote (CT or CC) had a 3.67-fold poor FEV1 
response to 8-week montelukast treatment than patients with 
the common alleles.
30 
Another study on IL-13 polymorphisms revealed a significant 
association between responsiveness to montelukast and IL-13 
-1,112 C/T polymorphism and the haplotype of IL-13 polymor-
phisms.
31Pharmacogenomics of Asthma Treatment
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INTERACTION BETWEEN GENETIC VARIATIONS AND 
ANTICHOLINERGICS
Although the effectiveness of long-acting anticholinergics is 
well established for managing chronic obstructive pulmonary 
disease, their roles in asthma management remain controver-
sial. Recently, several studies have suggested the efficacy of an-
ticholinergics in severe asthma,
32,33 and interest about the use of 
long-acting anticholinergics (e.g. tiotropium bromide) for asth-
ma have increased. We published a pharmacogenetic study on 
tiotropium bromide,
34 which included 138 severe asthmatics 
with decreased lung function who were taking conventional 
medications, with 18 μg of tiotropium added once daily. Re-
sponders were defined as those who improved ≥15% and 200 
ml in FEV1 and who maintained the therapy for at least 8 succes-
sive weeks. The results showed that 33.3% responded to tiotropi-
um, and Arg16Gly in ADRB2 was significantly associated with 
the tiotropium response (P=0.003) (Fig. 3). These results sug-
gest that as many as 30% of severe asthmatics benefited from 
adding tiotropium, and that Arg16Gly in ADRB2 may be a use-
ful marker for tiotropium response.
CONCLUDING REMARKS
Pharmacogenomics has the potential to revolutionize asthma 
therapy. Emerging information and pharmacogenomic study 
results indicate that standard treatment guidelines cannot be 
uniformly applied to the entire disease population. Understand-
ing the impact of genetic variations on the therapy response can 
decrease side effects and improve patient outcomes. Results 
from a larger number of asthma studies with different popula-
tions will be useful for establishing new asthma treatment guide-
lines and will help realize the ultimate goal of personalized 
medicine for asthma in the near future. 
REFERENCES
1. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald 
M, Gibson P, Ohta K, O’Byrne P, Pedersen SE, Pizzichini E, Sullivan 
SD, Wenzel SE, Zar HJ. Global strategy for asthma management 
and prevention: GINA executive summary. Eur Respir J 2008;31: 
143-78.
2. Lugogo NL, Kraft M. Epidemiology of asthma. Clin Chest Med 2006; 
27:1-15, v.
3. Jee HM, Kim KW, Kim CS, Sohn MH, Shin DC, Kim KE. Prevalence 
of asthma, rhinitis and eczema in korean children using the Inter-
national Study Of Asthma and Allergies In Childhood (ISAAC) ques-
tionnaires. Pediatr Allergy Respir Dis 2009;19:165-72. Korean.
4. Lee SI. Prevalence of childhood asthma in Korea: international study 
of asthma and allergies in childhood. Allergy Asthma Immunol Res 
2010;2:61-4.
5. Cho SH, Park HW, Rosenberg DM. The current status of asthma in 
Korea. J Korean Med Sci 2006;21:181-7.
6. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pau-
wels RA, Pedersen SE; GOAL Investigators Group. Can guideline-
defined asthma control be achieved? The Gaining Optimal Asthma 
ControL study. Am J Respir Crit Care Med 2004 15;170:836-44.
7. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic re-
sponses in asthma. Br Med Bull 2000;56:1054-70.
8. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor 
function, response, and regulation. J Allergy Clin Immunol 2006; 
117:18-24; quiz 5.
9. Maxwell TJ, Ameyaw MM, Pritchard S, Thornton N, Folayan G, 
Githang’a J, Indalo A, Tariq M, Mobarek A, Evans DA, Ofori-Adjei 
D, Templeton AR, McLeod HL. Beta-2 adrenergic receptor geno-
types and haplotypes in different ethnic groups. Int J Mol Med 
2005;16:573-80.
10. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymor-
phisms of the human beta 2-adrenergic receptor impart distinct 
agonist-promoted regulatory properties. Biochemistry 1994;33: 
9414-9.
11. Cho SH, Oh SY, Bahn JW, Choi JY, Chang YS, Kim YK, Min KU, Kim 
YY. Association between bronchodilating response to short-acting 
beta-agonist and non-synonymous single-nucleotide polymor-
phisms of beta-adrenoceptor gene. Clin Exp Allergy 2005;35:1162-7.
12. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson 
JA. Impact of genetic polymorphisms of the beta2-adrenergic re-
ceptor on albuterol bronchodilator pharmacodynamics. Clin Phar-
macol Ther 1999;65:519-25.
13. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chin-
chilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunsel-
man S, Lazarus SC, Lemanske RF, Martin RJ, McLean DE, Peters 
SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN. 
The effect of polymorphisms of the beta(2)-adrenergic receptor on 
the response to regular use of albuterol in asthma. Am J Respir Crit 
Care Med 2000;162:75-80.
14. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town 
GI. Asthma exacerbations during long term beta agonist use: influ-
ence of beta(2) adrenoceptor polymorphism. Thorax 2000;55:762-7.
15. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF, Jr., Boushey 
HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ, Di-
Mango E, Kraft M, Leone F, Martin RJ, Peters SP, Szefler SJ, Liu W, 
Israel E. beta-Adrenergic receptor polymorphisms and response to 
Fig. 3.  The response to tiotropium based on genotype-difference of ADRB2.
34
Arg16Arg (n=21)
P=0.003
Arg16Gly+Gly16Gly (n=59)
R
e
s
p
o
n
d
e
r
 
%
60
45
30
15
0Cho
Allergy Asthma Immunol Res. 2010 July;2(3):177-182.  doi: 10.4168/aair.2010.2.3.177
Volume 2, Number 3, July 2010
182 http://e-aair.org
salmeterol. Am J Respir Crit Care Med 2006;173:519-26.
16. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, 
Goldman M. Effect of ADRB2 polymorphisms on response to lon-
gacting beta2-agonist therapy: a pharmacogenetic analysis of two 
randomised studies. Lancet 2007;370:2118-25.
17. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and 
resistance. J Allergy Clin Immunol 2006;117:522-43.
18. Bray PJ, Cotton RG. Variations of the human glucocorticoid recep-
tor gene (NR3C1): pathological and in vitro mutations and poly-
morphisms. Hum Mutat 2003;21:557-68.
19. Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman 
EK, Liggett SB, Gelfand EW, Rosenwasser LJ, Richter B, Israel E, 
Wechsler M, Gabriel S, Altshuler D, Lander E, Drazen J, Weiss ST. 
Corticosteroid pharmacogenetics: association of sequence vari-
ants in CRHR1 with improved lung function in asthmatics treated 
with inhaled corticosteroids. Hum Mol Genet 2004;13:1353-9.
20. Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, Adcock IM. 
Expression and activity of histone deacetylases in human asthmat-
ic airways. Am J Respir Crit Care Med 2002;166:392-6.
21. Bhavsar P, Ahmad T, Adcock IM. The role of histone deacetylases in 
asthma and allergic diseases. J Allergy Clin Immunol 2008;121:580-4.
22. Fischer DD, Cai R, Bhatia U, Asselbergs FA, Song C, Terry R, Trogani 
N, Widmer R, Atadja P, Cohen D. Isolation and characterization of 
a novel class II histone deacetylase, HDAC10. J Biol Chem 2002; 
277:6656-66.
23. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pil-
lari A, Israel E, Schork N, Silverman ES, Katz DA, Drajesk J. Phar-
macogenetic association between ALOX5 promoter genotype and 
the response to anti-asthma treatment. Nat Genet 1999;22:168-70.
24. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, Wang J, 
Sylvester J, Holbrook J, Wise R, Weiss ST, Barnes K. Influence of leu-
kotriene pathway polymorphisms on response to montelukast in 
asthma. Am J Respir Crit Care Med 2006;173:379-85.
25. Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki 
T, Hakuno H, Fukunaga K, Suzuki Y, Kanazawa M, Yamaguchi K. 
Leukotriene C4 synthase gene A(-444)C polymorphism and clini-
cal response to a CYS-LT(1) antagonist, pranlukast, in Japanese pa-
tients with moderate asthma. Pharmacogenetics 2002;12:565-70.
26. Kim SH, Ye YM, Hur GY, Lee SK, Sampson AP, Lee HY, Park HS. Cys-
LTR1 promoter polymorphism and requirement for leukotriene re-
ceptor antagonist in aspirin-intolerant asthma patients. Pharma-
cogenomics 2007;8:1143-50.
27. Klotsman M, York TP, Pillai SG, Vargas-Irwin C, Sharma SS, van den 
Oord EJ, Anderson WH. Pharmacogenetics of the 5-lipoxygenase 
biosynthetic pathway and variable clinical response to montelu-
kast. Pharmacogenet Genomics 2007;17:189-96.
28. Currie GP, Lima JJ, Sylvester JE, Lee DK, Cockburn WJ, Lipworth BJ. 
Leukotriene C4 synthase polymorphisms and responsiveness to 
leukotriene antagonists in asthma. Br J Clin Pharmacol 2003;56: 
422-6.
29. Lee SY, Kim HB, Kim JH, Kim BS, Kang MJ, Jang SO, Seo HJ, Hong 
SJ. Responsiveness to montelukast is associated with bronchial hy-
perresponsiveness and total immunoglobulin E but not polymor-
phisms in the leukotriene C4 synthase and cysteinyl leukotriene 
receptor 1 genes in Korean children with exercise-induced asthma 
(EIA). Clin Exp Allergy 2007;37:1487-93.
30. Kim JH, Lee SY, Kim HB, Jin HS, Yu JH, Kim BJ, Kim BS, Kang MJ, 
Jang SO, Hong SJ. TBXA2R gene polymorphism and responsive-
ness to leukotriene receptor antagonist in children with asthma. 
Clin Exp Allergy 2008;38:51-9.
31. Kang MJ, Lee SY, Kim HB, Yu J, Kim BJ, Choi WA, Jang SO, Hong SJ. 
Association of IL-13 polymorphisms with leukotriene receptor an-
tagonist drug responsiveness in Korean children with exercise-in-
duced bronchoconstriction. Pharmacogenet Genomics 2008;18: 
551-8.
32. Iwamoto H, Yokoyama A, Shiota N, Shoda H, Haruta Y, Hattori N, 
Kohno N. Tiotropium bromide is effective for severe asthma with 
noneosinophilic phenotype. Eur Respir J 2008;31:1379-80.
33. Kapoor AS, Olsen SR, O’Hara C, Puttagunta L, Vethanayagam D. 
The efficacy of tiotropium as a steroid-sparing agent in severe asth-
ma. Can Respir J 2009;16:99-101.
34. Park HW, Yang MS, Park CS, Kim TB, Moon HB, Min KU, Kim YY, 
Cho SH. Additive role of tiotropium in severe asthmatics and Arg-
16Gly in ADRB2 as a potential marker to predict response. Allergy 
2009;64:778-83.
 